Plegridy

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
25-04-2023

Ingredient activ:

peginterferon beta-1a

Disponibil de la:

Biogen Netherlands B.V.

Codul ATC:

L03AB13

INN (nume internaţional):

peginterferon beta-1a

Grupul Terapeutică:

Immunostimulants,

Zonă Terapeutică:

Multiple Sclerosis

Indicații terapeutice:

Treatment of relapsing remitting multiple sclerosis in adult patients.

Rezumat produs:

Revision: 24

Statutul autorizaţiei:

Authorised

Data de autorizare:

2014-07-18

Prospect

                                50
B. PACKAGE LEAFLET
51
PACKAGE LEAFLET: INFORMATION FOR THE USER
PLEGRIDY 63 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
PLEGRIDY 94 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
PLEGRIDY 125 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
peginterferon beta-1a
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
WHAT PLEGRIDY IS AND WHAT IT IS USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PLEGRIDY
3.
HOW TO USE PLEGRIDY
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE PLEGRIDY
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
7.
INSTRUCTIONS FOR INJECTING PLEGRIDY PRE-FILLED SYRINGE
1.
WHAT PLEGRIDY IS AND WHAT IT IS USED FOR
WHAT PLEGRIDY IS
The active substance in Plegridy is peginterferon beta-1a.
Peginterferon beta-1a is a modified
long-acting form of interferon. Interferons are natural substances
made in the body to help protect
from infections and diseases.
WHAT PLEGRIDY IS USED FOR
THIS MEDICINE IS USED TO TREAT RELAPSING-REMITTING MULTIPLE SCLEROSIS
(MS) IN ADULTS AGED 18 OR
OVER.
MS is a long term illness that affects the central nervous system
(CNS), including the brain and spinal
cord, in which the body’s immune system (its natural defences)
damages the protective layer (myelin)
that surrounds the nerves in the brain and spinal cord. This disrupts
the messages between the brain
and other parts of the body, causing the symptoms of MS. Patients with
relapsing-remitting MS have
periods when the disease is not active (remission) in between
flare-ups of symptom
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Plegridy 63 micrograms solution for injection in pre-filled syringe
Plegridy 94 micrograms solution for injection in pre-filled syringe
Plegridy 125 micrograms solution for injection in pre-filled syringe
Plegridy 63 micrograms solution for injection in pre-filled pen
Plegridy 94 micrograms solution for injection in pre-filled pen
Plegridy 125 micrograms solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Plegridy 63 micrograms solution for injection in pre-filled syringe
(for subcutaneous use)
Each pre-filled syringe contains 63 micrograms of peginterferon
beta-1a* in 0.5 mL solution for
injection.
Plegridy 94 micrograms solution for injection in pre-filled syringe
(for subcutaneous use)
Each pre-filled syringe contains 94
micrograms of peginterferon beta-1a* in 0.5 mL solution for
injection.
Plegridy 125 micrograms solution for injection in pre-filled syringe
(for subcutaneous use)
Each pre-filled syringe contains 125 micrograms of peginterferon
beta-1a* in 0.5 mL solution for
injection.
Plegridy 125 micrograms solution for injection in pre-filled syringe
(for intramuscular use)
Each pre-filled syringe contains 125 micrograms of peginterferon
beta-1a* in 0.5 mL solution for
injection.
Plegridy 63 micrograms solution for injection in pre-filled pen (for
subcutaneous use)
Each pre-filled pen contains 63 micrograms of peginterferon beta-1a*
in 0.5 mL solution for injection.
Plegridy 94 micrograms solution for injection in pre-filled pen (for
subcutaneous use)
Each pre-filled pen contains 94 micrograms of peginterferon beta-1a*
in 0.5 mL solution for injection.
Plegridy 125 micrograms solution for injection in pre-filled pen (for
subcutaneous use)Each pre-filled
pen contains 125 micrograms of peginterferon beta-1a* in 0.5 mL
solution for injection.
The dose indicates the quantity of the interferon beta-1a moiety of
peginterferon beta-1a without
consideration of the PEG moiety attached.
*The active sub
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 25-04-2023
Raport public de evaluare Raport public de evaluare bulgară 22-12-2020
Prospect Prospect spaniolă 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 25-04-2023
Raport public de evaluare Raport public de evaluare spaniolă 22-12-2020
Prospect Prospect cehă 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 25-04-2023
Raport public de evaluare Raport public de evaluare cehă 22-12-2020
Prospect Prospect daneză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 25-04-2023
Raport public de evaluare Raport public de evaluare daneză 22-12-2020
Prospect Prospect germană 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului germană 25-04-2023
Raport public de evaluare Raport public de evaluare germană 22-12-2020
Prospect Prospect estoniană 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 25-04-2023
Raport public de evaluare Raport public de evaluare estoniană 22-12-2020
Prospect Prospect greacă 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 25-04-2023
Raport public de evaluare Raport public de evaluare greacă 22-12-2020
Prospect Prospect franceză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 25-04-2023
Raport public de evaluare Raport public de evaluare franceză 22-12-2020
Prospect Prospect italiană 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 25-04-2023
Raport public de evaluare Raport public de evaluare italiană 22-12-2020
Prospect Prospect letonă 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 25-04-2023
Raport public de evaluare Raport public de evaluare letonă 22-12-2020
Prospect Prospect lituaniană 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 25-04-2023
Raport public de evaluare Raport public de evaluare lituaniană 22-12-2020
Prospect Prospect maghiară 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 25-04-2023
Raport public de evaluare Raport public de evaluare maghiară 22-12-2020
Prospect Prospect malteză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 25-04-2023
Raport public de evaluare Raport public de evaluare malteză 22-12-2020
Prospect Prospect olandeză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 25-04-2023
Raport public de evaluare Raport public de evaluare olandeză 22-12-2020
Prospect Prospect poloneză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 25-04-2023
Raport public de evaluare Raport public de evaluare poloneză 22-12-2020
Prospect Prospect portugheză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 25-04-2023
Raport public de evaluare Raport public de evaluare portugheză 22-12-2020
Prospect Prospect română 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului română 25-04-2023
Raport public de evaluare Raport public de evaluare română 22-12-2020
Prospect Prospect slovacă 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 25-04-2023
Raport public de evaluare Raport public de evaluare slovacă 22-12-2020
Prospect Prospect slovenă 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 25-04-2023
Raport public de evaluare Raport public de evaluare slovenă 22-12-2020
Prospect Prospect finlandeză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 25-04-2023
Raport public de evaluare Raport public de evaluare finlandeză 22-12-2020
Prospect Prospect suedeză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 25-04-2023
Raport public de evaluare Raport public de evaluare suedeză 22-12-2020
Prospect Prospect norvegiană 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 25-04-2023
Prospect Prospect islandeză 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 25-04-2023
Prospect Prospect croată 25-04-2023
Caracteristicilor produsului Caracteristicilor produsului croată 25-04-2023
Raport public de evaluare Raport public de evaluare croată 22-12-2020

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor